VYNE (VYNE Therapeutics) Short Interest


VYNE VYNE Therapeutics Inc VYNE
37 GF Score
Price $0.65
GF Value $0.55
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is VYNE Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

VYNE vs TPST, NXTC, QNCX: Short Interest Comparison

For the Biotechnology subindustry, VYNE Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VYNE Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where VYNE Therapeutics's Short Interest falls into.


VYNE
37GF Score
VYNE Therapeutics Inc VYNE
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VYNE Therapeutics (VYNE) Overvalued in 2026?

Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued. The current stock price of $0.65 is trading 18.2% above its estimated GF Value™ of $0.55. GuruFocus considers VYNE Therapeutics to be Modestly Overvalued.

Key valuation signals for VYNE:

  • Short Interest:
  • GF Value™: $0.55 vs. price of $0.65 (18.2% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VYNE Therapeutics Business Description

Address P.O. Box 125, Stewartsville, NJ, USA, 08886
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
37GF Score

Get the complete analysis for VYNE

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.55
GF Value